Publicacións en colaboración con investigadores/as de Cleveland Clinic (8)

2024

  1. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials

    Seminars in Arthritis and Rheumatism, Vol. 65

  2. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments

    Seminars in Arthritis and Rheumatism, Vol. 65

  3. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2021

  1. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 9, pp. 1137-1146

  2. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 3, pp. 593-600

2020

  1. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

    Pain, Vol. 161, Núm. 9, pp. 2068-2078

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

2015

  1. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility

    American Journal of Human Genetics, Vol. 96, Núm. 4, pp. 565-580